Prognostic and predictive value of a breast cancer expression signature in localized prostate cancer
A partir de l'analyse de 3 782 échantillons de cancer de la prostate à l'aide du test PAM50 initialement utilisé pour classifier les tumeurs mammaires, cette étude identifie trois sous-types tumoraux (sous-type luminal A ou B et sous-type basal), puis évalue leur association avec la survie des patients et la réponse aux traitements anti-androgéniques
Biomarkers are developed for specific contexts of use following a defined paradigm that requires an analytically-valid assay and a sequence of clinical studies whose objective is to prove clinical utility: that patient outcomes are improved through the use of the biomarker test relative to nonuse. In this issue, Zhao et al1 follow this paradigm by applying a US Food and Drug Administration-cleared and Conformité Européene-marked gene–expression-based classifier derived from breast cancer, called PAM50,2 to potential use as a predictive biomarker in localized prostate cancer.
JAMA Oncology , commentaire en libre accès, 2016